Only 14 pages are availabe for public view
olorectal cancer (CRC) is the third most frequently diagnosed cancer and the second leading cause of cancer death. Over 1.8 million new colorectal cancer cases and 881,000 deaths are estimated to occur in 2018, accounting for about1 in 10 cancer cases and deaths.
At the time of diagnosis, about 20% of CRC patients have already developed metastatic diseases. It is well known that the most common metastatic site for CRC patients is liver, followed by lung.
Over the past 30 years, there has been a great interest in clinical and molecular prognostic factors in metastatic (m) colorectal cancer (CRC).
Despite recent advances in the management of colorectal cancer and new developments of cancer surveillance, the majority of colorectal cancer patients are still diagnosed at an advanced stage when the therapeutic options are limited. It is necessary to find effective biomarker and receptor-mediated tumor-targeted therapy, which could improve prediction of disease outcomes, to improve response and survival rates.
Many researchers have reported that high expression of some markers indicates bad clinical features and poor prognosis, and HER-2 was one of the reported cancer markers.
The purpose of this study was to identify the incidence of HER2 in metastatic colorectal cancer including synchronous and metachronous metastasis, and to clarify its clinical significance as prognostic factor and predictive factor to different types of chemotherapy.
Analysis of available paraffin blocks for 70 patients confirmed as metastatic colorectal cancer according to results of our study,HER2 incidence (including HER2 score +2 and +3 IHC)is 8.57% (6 out of 70 cases with 4 cases scoring +3 and 2 cases +2IHC).
Analysis of response to first and second line chemotherapy in this study has shown significant shorter PFS for HER2 positive cases.
It also revealed tendency for shorter OS for HER2 positivity.
Analysis of different clinicopathological parameters revealed no statistically significant association with HER2 positivity, however a trend towards female patients and left sided tumours to be involved.